Management of Acute Decompensated Heart FailureChristopher O'Connor, Wendy Gattis Stough, Miahai Gheorghiade, Kirkwood F. Adams CRC Press, 29 nov 2005 - 644 páginas Although the majority of heart failure represents the exacerbation of chronic disease, about 20% will present as a first time diagnosis. And although there are a number of intravenous agents that can be used for acute decompensated heart failure, there are no national guidelines currently available. Edited by a well-known expert and his team of con |
Índice
| 3 | |
CHAPTER 2 Acute heart failure nomenclature pathophysiology and outcome measures | 19 |
CHAPTER 3 Clinical profile of the acute heart failure patient | 39 |
CHAPTER 4 Sexrelated differences in heart failure | 53 |
CHAPTER 5 Heart failure in the elderly | 71 |
de novo heart failure decompensated heart failure and advanced refractory heart failure | 87 |
diagnosis prognosis and treatment | 95 |
CHAPTER 8 Pathophysiology of the cardiorenal syndrome in acture heart failure | 113 |
CHAPTER 21 Treatment of acute heart failure in patients with preserved systolic function | 325 |
CHAPTER 22 Inotropes and other new therapies for acute heart failure | 339 |
CHAPTER 23 Diuretics and newer therapies for sodium and edema management in decompensated heart failure | 349 |
CHAPTER 24 Contemporary aspects of intravenous vasodilator therapy with nesiritide or nitrates in acute heart failure | 361 |
CHAPTER 25 Pacing therapy for acute decompensated heart failure | 371 |
CHAPTER 26 Implantable cardioverter defibrillators and biventricular devices in acute heart failure | 387 |
CHAPTER 29 Mechanical circulatory support for acute heart failure | 429 |
CHAPTER 30 Left ventricular reconstruction for ischemic failing ventricle | 443 |
Diagnosis and Evaluations of the Acute Heart Failure Patient | 125 |
assessment of dyspnea and other physical examination parameters | 127 |
CHAPTER 10 Biologic markers in acture heart failure | 151 |
focus on the electrocardiogram and chest xray | 165 |
CHAPTER 12 Noninvasive hemodynamic monitoring of the acture heart failure patient | 179 |
Comorbidities in the Acute Heart Failure Patient | 191 |
CHAPTER 13 Arrhythmias in acute heart failure | 193 |
CHAPTER 14 Mechanical complications of acute decompensated heart failure | 209 |
CHAPTER 15 Cardiogenic shock | 221 |
CHAPTER 16 Hypertension in acute decompensated heart failure | 241 |
CHAPTER 17 Psychiatric and psychosocial risks in acutely decompensated chronic heart failure patients | 253 |
CHAPTER 18 Anemia in acute and chronic heart failure | 273 |
CHAPTER 19 Acute pulmonary embolism | 285 |
diagnostic and management considerations | 301 |
Treatment Strategies | 323 |
CHAPTER 31 The Acorn Cardiac Support Device as a therapy for heart failure | 453 |
CHAPTER 32 The role of continuous positive airway pressure in the management of decompensated heart failure complicated by acute pulmonary e... | 461 |
a need for more data | 469 |
CHAPTER 34 Calcium sensitizers in acute heart failure | 479 |
CHAPTER 35 Vasopressin antagonists | 497 |
Issues in the Management of Acute Heart Failure | 521 |
CHAPTER 37 Advanced nursing aspects of acute heart failure | 523 |
CHAPTER 38 The role of the pharmacist in caring for patients with acute heart failure | 529 |
CHAPTER 39 Economics and quality of life in the advanced heart failure patient | 535 |
CHAPTER 40 Diseae management in the advanced heat failure patient | 555 |
CHAPTER 41 Endoflife care in the acute heart failure patient | 569 |
| 585 | |
Back cover | 605 |
Otras ediciones - Ver todo
Management of Acute Decompensated Heart Failure Christopher O'Connor,Wendy Gattis Stough,Miahai Gheorghiade,Kirkwood F. Adams No hay ninguna vista previa disponible - 2005 |
Términos y frases comunes
activation acute addition ADHF agents artery assessment associated benefit blood pressure cardiac cardiogenic shock Cardiol cause changes chronic heart failure Circulation clinical Coll Cardiol compared congestive heart failure coronary death decompensated decreased depression device diagnosis diastolic differences disease diuretic dose drug dysfunction dyspnea edema effects elevated Engl et al evaluation exercise factors Fail Figure fluid function heart failure patients hemodynamic higher hospital hypertension important improvement increased indicate inhibitors initial intravenous ischemia ischemic lead left ventricular levels levosimendan LVEF mean measures mechanical mortality myocardial infarction normal occurs outcomes output pacing patients with heart potential present pressure pulmonary randomized recent reduced renal reported response risk role severe shown significant suggested symptoms systolic Table therapy tion treated treatment trial volume women